Novo Nordisk Enters Agreement with Vivani Medical to Evaluate Ultra-Long-Acting Semaglutide Implant for Chronic Weight Management
Key Insights
Novo Nordisk has signed a non-exclusive agreement with Vivani Medical to evaluate NPM-139, a miniature semaglutide drug implant utilizing the NanoPortal platform technology for chronic weight management.
Vivani expects to initiate a Phase 1, randomized, first-in-human study in mid-2026 comparing the NPM-139 implant with Wegovy injections, assessing safety, pharmacokinetics, and tolerability.
The NanoPortal implant platform is designed to provide near-constant, controlled drug release over extended periods, potentially enabling once- or twice-yearly dosing for GLP-1 (search) therapies.
Novo Nordisk and Vivani Medical, Inc. have entered into a new agreement enabling the Danish pharmaceutical giant to conduct a non-exclusive internal evaluation of NPM-139, an ultra-long-acting semaglutide drug implant under development for chronic weight management. The agreement, announced on July 7, 2026, signals Novo Nordisk's strategic interest in implantable drug delivery technologies that could reshape the GLP-1 (search) receptor agonist landscape.
NPM-139 leverages Vivani's proprietary NanoPortal platform, a subdermal implant technology engineered to deliver drug molecules steadily over extended periods. The implant is designed to provide patients with a once- or twice-yearly treatment option, a significant departure from the current weekly injection regimens associated with marketed GLP-1 (search) therapies such as Wegovy and Ozempic.
"There are no exclusivity provisions for NPM-139, or Vivani's proprietary NanoPortal technology associated with this agreement," the company stated, preserving Vivani's flexibility to pursue additional partnerships.
Clinical Development Pathway
Vivani expects to initiate a Phase 1, randomized, first-in-human study in mid-2026 to evaluate the NPM-139 semaglutide implant. The trial will use Wegovy injections as an active comparator, with primary objectives focused on characterizing the safety, pharmacokinetics, and tolerability of the implant. Successful completion of this study would support the initiation of a Phase 2 dose-ranging study.
"The new agreement announced today supporting our semaglutide implant program in chronic weight management demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application," said Adam Mendelsohn, Ph.D., President and CEO of Vivani Medical. "This agreement reinforces our confidence regarding the market opportunity for our GLP-1 (search) implants under development."
Mendelsohn further emphasized the patient-centric rationale behind the technology: "We believe that our NanoPortal implants under development, including NPM-139, could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary."
The NanoPortal Platform Technology
Vivani's NanoPortal is a proprietary implant platform distinguished by its nanopore technology, which can be precisely tailored to the size of specific drug molecules to achieve what the company describes as the "Goldilocks Effect"—pores just large enough to enable steady, long-term drug release without the fluctuations associated with traditional delivery methods.
Unlike many extended-release implants, NanoPortal can deliver both small-molecule drugs and larger hydrophilic molecules, including peptides and proteins, substantially expanding its potential therapeutic applications. The device features a simple, miniature design with no pumps or electronics, facilitating straightforward subdermal insertion and removal while maximizing drug capacity. Its flexible architecture can accommodate different drug formulations and dosing durations.
Addressing Medication Non-Adherence
The development of ultra-long-acting implants targets a persistent challenge in chronic disease management: medication non-adherence. According to Vivani, non-adherence affects approximately 50% of patients, including those taking daily oral medications. By eliminating the need for frequent self-administration, implantable systems like NPM-139 aim to guarantee adherence and improve patient tolerance to their medication.
Vivani is developing a portfolio of GLP-1 (search)-based implants targeting metabolic diseases including obesity (search) and type 2 diabetes (search). The company's stated goal is to provide patients with the opportunity to realize the full potential benefit of their medication by circumventing the challenges associated with daily or weekly administration of oral and injectable therapies, including tolerability issues and loss of efficacy.
Novo Nordisk's GLP-1 (search) Leadership
Novo Nordisk has established a dominant position in the GLP-1 (search) receptor agonist market through its portfolio of semaglutide-based products. Rybelsus, launched in 2019, remains the world's first and only oral GLP-1 receptor agonist, made possible by engineering a more stable form of semaglutide combined with the absorption enhancer SNAC. Ozempic, the injectable formulation, provides an alternative for glycemic control in type 2 diabetes (search), while Wegovy is FDA-approved for chronic weight management and for reducing the risk of major cardiovascular events in adults with obesity (search) and established heart disease.
The evaluation agreement with Vivani represents a potential next frontier in GLP-1 (search) delivery, exploring whether implantable technology can further extend the duration of action and improve the patient experience in chronic weight management.